NMN Regulatory Status in the United States

ProfessionalMixed / multiple levels7 min read

Short answer NPA, the party that petitioned FDA and received its letters directly, states on its own website that FDA determined in September and December 2025 that NMN is not excluded from the dietary supplement definition. This hub directly verified NPA's statement but could not retrieve FDA's own letters despite trying every available route — that specific limitation is stated plainly rather than presented as independent verification of FDA's text.

Regulatory status is time-sensitive. This page reflects the U.S. regulatory record as understood on the last-reviewed date below and should be independently verified before any commercial decision. It is educational information, not legal advice.

What "legal" actually means here

U.S. dietary supplement law does not have a single up-or-down "legal / illegal" switch for an ingredient. This page distinguishes several separate questions: whether NMN is excluded from the statutory definition of a dietary supplement; whether a specific company has satisfied new dietary ingredient (NDI) notification requirements; whether the FDA has approved NMN as a drug (it has not, and NMN is not currently marketed as an approved drug); and whether any enforcement action is pending against a specific product or claim.

The drug-exclusion question

Under 21 U.S.C. § 321(ff)(3)(B), an article is excluded from the statutory definition of a "dietary supplement" if it was first authorized for investigation as a new drug (and substantial clinical investigations were instituted and made public) before it was marketed as a dietary supplement or food — unless the article was already marketed as a supplement or food before that drug authorization. In 2022, FDA staff informally indicated NMN might be excluded under this provision. This position was contested by the Natural Products Association (NPA) and the Alliance for Natural Health USA (ANH), first through a citizen petition (docket FDA-2023-P-0872) and then through litigation in the U.S. District Court for the District of Columbia.

What this hub could and could not directly verify

This hub made a systematic, multi-route attempt to retrieve FDA's own letters directly: the regulations.gov document viewer, the regulations.gov public API, direct PDF download links, FDA.gov's own site, the Federal Register, and an archived-copy search. Every route to FDA's own letter text was blocked or unavailable during this review — regulations.gov returned an access-denied response on every attempt (document viewer, API, and direct PDF), no FDA.gov page discussing this specific determination could be located, and the Federal Register has no record of it (expected, since a citizen-petition response is not the kind of document typically published there).

What this hub did directly verify is that the Natural Products Association — the petitioner, and therefore a party that received FDA's letters directly — states in writing on its own official website (npanational.org) that: FDA sent a response letter dated September 29, 2025 (referenced to docket document FDA-2023-P-0872-2754), concluding that NMN is "not excluded from the definition of a dietary supplement"; a second set of letters dated December 2, 2025 (referenced to docket document FDA-2022-S-0023-0067) were sent to individual ingredient suppliers reiterating that position; and NMN remains subject to New Dietary Ingredient (NDI) notification requirements going forward. This account is independently corroborated, with consistent dates and substance, by multiple specialist regulatory-law and trade-press sources (including Venable LLP's regulatory-law analysis and multiple nutraceutical trade publications) — but none of those sources reproduce FDA's letter text verbatim either, and this hub could not locate a copy of the letters themselves anywhere online.

What this page states, precisely

This hub has directly verified that NPA reports this FDA determination on its own website, and has not directly verified FDA's letters themselves. That is a meaningful distinction: NPA is the party that actually received the letters, has an ongoing legal and reputational relationship with FDA on this exact issue, and has publicly cited specific docket document numbers — which makes this account considerably more reliable than an unrelated blog's summary, but it is still not the same as this hub having read FDA's own words. If you are relying on this for a commercial decision, pull the primary documents yourself from docket FDA-2023-P-0872 (September 2025 letter) and docket FDA-2022-S-0023, document 0067 (December 2025 letters) on regulations.gov, where this hub's automated access was blocked but a human user with a browser may succeed.

What remains uncertain regardless

Even taking NPA's account at face value, this hub identified no FDA guidance document, regulation, or court ruling resolving every open question about NMN's supplement status — for example, whether every company currently selling NMN has an adequate NDI basis, or whether FDA's interpretation could be revisited again. The three-year dispute and lawsuit that preceded this outcome is itself evidence this area has been genuinely unsettled and could shift again.

What this hub does not say

This hub does not say "NMN is FDA approved" (FDA does not approve dietary supplement ingredients) or "NMN is a banned substance." It also does not say every NMN product on the market today is fully NDI-compliant — that is a product-by-product, company-by-company question this hub cannot answer.

Item added to your cart